Form 8-K - Current report:
SEC Accession No. 0000950170-24-105182
Filing Date
2024-09-10
Accepted
2024-09-10 16:39:55
Documents
15
Period of Report
2024-09-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20240906.htm   iXBRL 8-K 55580
2 EX-10.1 kalv-ex10_1.htm EX-10.1 172698
3 EX-10.2 kalv-ex10_2.htm EX-10.2 170056
4 EX-10.3 kalv-ex10_3.htm EX-10.3 171160
5 EX-99.1 kalv-ex99_1.htm EX-99.1 18556
  Complete submission text file 0000950170-24-105182.txt   793657

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20240906.xsd EX-101.SCH 24861
17 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20240906_htm.xml XML 4718
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 241290531
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)